Serum peptide profiles in patients with carcinoid tumors
Autor: | Kristine Calhoun, Su Ellen Toth-Fejel, Julie Cheek, Rodney F. Pommier |
---|---|
Rok vydání: | 2003 |
Předmět: |
Calcitonin
Male medicine.medical_specialty Carcinoid tumors Vasoactive intestinal peptide Carcinoid Tumor Substance P Pancreatic Polypeptide Pancreastatin chemistry.chemical_compound Predictive Value of Tests Internal medicine Gastrins Biomarkers Tumor medicine Humans Pancreatic polypeptide Neurotensin Gastrin business.industry General Medicine Peptide secretion Pancreatic Hormones medicine.disease Endocrinology Gastrin-Releasing Peptide chemistry Disease Progression Chromogranin A Female Surgery Peptides business hormones hormone substitutes and hormone antagonists Vasoactive Intestinal Peptide |
Zdroj: | The American Journal of Surgery. 186:28-31 |
ISSN: | 0002-9610 |
DOI: | 10.1016/s0002-9610(03)00115-6 |
Popis: | Background Patterns of elevated serum peptides may reveal additional markers and permit better classification of tumors based on (secondary) peptide secretion. Methods Fasting peptide profiles were obtained from 31 carcinoid patients. vasoactive intestinal peptide (VIP), pancreatic polypeptide (PP), neurotensin, substance P, gastrin-releasing polypeptide (GRP), calcitonin, gastrin, and pancreastatin were measured. Peptide elevation patterns were correlated with disease sites, syndrome, and survival. Results Elevations in patients were as follows: VIP 0%, PP 13%, neurotensin 10%, substance P 20%, GRP 3%, calcitonin 10%, and gastrin 3%. There were no consistent patterns of elevated peptides with regard to site or syndrome. Pancreastatin was elevated in 81% of profiles and was the only abnormal peptide in 57% of patients. Conclusion Peptide profile results do not permit improved classification, predict syndrome development, or correlate with survival. In contrast, pancreastatin is elevated in most cases and may be utilized to monitor disease progression and evaluate response to therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |